Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions

Area of Science:

• Psychiatry
• Endocrinology
• Pharmacology

Background:

• Schizophrenia patients exhibit high rates of cardiometabolic risk factors.
• Antipsychotic medication use exacerbates these risks, impacting patient health.
• Existing interventions aim to mitigate these medication-induced adverse effects.

Purpose of the Study:

• To review pharmacologic interventions for managing antipsychotic-related cardiometabolic changes in schizophrenia.
• To evaluate the efficacy of metformin, topiramate, and aripiprazole in improving metabolic and psychopathological outcomes.

Main Methods:

• Review of randomized controlled trials and literature on pharmacologic interventions.
• Analysis of studies examining metformin, topiramate, and aripiprazole for cardiometabolic and psychiatric effects.

Main Results:

• Metformin demonstrates significant improvements in weight, glycemic control, and lipid metabolism.
• Topiramate and aripiprazole show potential benefits for both metabolic outcomes and psychopathology.
• These interventions offer a promising approach to managing adverse effects of antipsychotic treatment.

Conclusions:

• Metformin is the most studied intervention, with robust evidence for improving cardiometabolic parameters.
• Topiramate and aripiprazole present dual benefits, addressing both metabolic and psychiatric symptoms.
• Further research is crucial to address remaining questions and optimize treatment strategies.